Ramping up funding for cancer research

John E. Niederhuber, M.D., named this summer by President Bush to become the 13th director of the National Cancer Institute (NCI), faces the difficult task of balancing pressures to reduce costs with the need to expand the nation's investment in cancer research.

Related Videos
Related Content

Phase 3 Data for Bimekizumab Shows Well Maintained Response

March 21st 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

FDA Approves Adalimumab-Adaz High-Concentration Formulation

March 21st 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Skin Barrier 101: Keep Up with What Your Patients Are Reading

March 21st 2023

Oral Ivarmacitinib Demonstrates Significant Atopic Dermatitis Improvement

March 21st 2023

Phase 3 Data for Bimekizumab Shows Well Maintained Response

March 21st 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

FDA Approves Adalimumab-Adaz High-Concentration Formulation

March 21st 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Skin Barrier 101: Keep Up with What Your Patients Are Reading

March 21st 2023

Oral Ivarmacitinib Demonstrates Significant Atopic Dermatitis Improvement

March 21st 2023

Phase 3 Data for Bimekizumab Shows Well Maintained Response

March 21st 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

FDA Approves Adalimumab-Adaz High-Concentration Formulation

March 21st 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Skin Barrier 101: Keep Up with What Your Patients Are Reading

March 21st 2023

Oral Ivarmacitinib Demonstrates Significant Atopic Dermatitis Improvement

March 21st 2023
© 2023 MJH Life Sciences

All rights reserved.